











Annual Report 2020



hoesierSM
CANCER RESEARCH NETWORK

Board of Directors



Christopher Fausel, MD, MHA, BCOP, *Chair*



Shadia Jalal, MD, *Chief Scientific Officer*



Annette Moore, MD, *Secretary*



Christopher Wayne, MS, MBA, FACHE, CMPE, *Treasurer*



Alesha Arnold, RN



Kerry Bridges, MBA, RN, CCRC



Noah Hahn, MD



Christopher LeMasters, MBA



Patrick Loehrer, Sr., MD



Timothy Ratliff, PhD



Ted Stansbury



Richard Zellars, MD

Hoosier Cancer Research Network's vision and mission is to form **unparalleled** relationships between academic, community, pharmaceutical, and biotech collaborators with the goal of **advancing** cancer research, education, and patient advocacy.

Our **highly qualified** team provides **comprehensive** study management and support, from conception and study design through project completion and publication.

Chairman and CSO

Perspectives

As part of the nation's workforce on the front lines of patient care, we know all too well how challenging this past year has been on our healthcare system. Many of our colleagues have taken on new responsibilities to ensure the best possible care for all patients who walk through the doors of our hospitals and clinics.

More than ever before, this past year has crystallized the importance of establishing and strengthening collaborations across the hallway and across institutions, and we are deeply proud of the role Hoosier Cancer Research Network has played in ensuring such collaborations not only exist but also thrive in times like these.

Together, all members of the HCRN team have played their part, and then some, to bring hope to patients. We thank our academic and community sites, sponsor-investigators, site PIs and co-PIs, study teams, funders, and the talented and committed leadership and staff of Hoosier Cancer Research Network for ensuring we never missed a beat during 2020. Most importantly, we thank each and every patient who enrolled in a clinical trial. Your participation is a gift to future generations of cancer patients and enables researchers to develop safer and more effective ways to treat cancer.

We know that cancer never eases its assault on our loved ones. As long as there is progress to be made, together we will continue the good work that must be done.



**Christopher A. Fausel,
PharmD, MHA, BCOP**

Oncology Precision Genomics Pharmacist,
Indiana University Melvin and Bren Simon
Comprehensive Cancer Center



Shadia I. Jalal, MD

Associate Professor of Medicine
Indiana University School of Medicine

One Team. *Infinite Possibilities.*



Executive Director

Perspectives



Cyndi Burkhardt, RN

Executive Director
Hoosier Cancer Research Network


In the years since I joined Hoosier Cancer Research Network in 2006, change has been a common thread that has woven through our “story.” The past year, perhaps more than any other, has reminded me how important it is for organizations to be nimble and resilient in the face of many challenges.

HCRN is fortunate to be guided by a board of directors who understand the complex and rapidly evolving space for conducting multi-center, investigator-initiated clinical research studies. Our management team and staff represent decades of expertise and leadership in highly specialized areas, strengthened by a culture of flexibility that embraces change when required to meet the needs of the moment.

While being mindful that many organizations did not survive the year or significantly curtailed their scope of operations, I am deeply grateful that HCRN held steady throughout, remained true to our founding mission, and emerged stronger in many respects than when the year began. One of the greatest lessons we have learned is that, while the COVID-19 pandemic created many hurdles that had to be cleared for research operations to function normally, it did not slow the pace of our research development. Our working groups grew steadily throughout 2020, both in participation and in the number of LOIs received. With strong continuing support from industry funders, we ended the year with 71 active studies and 21 approved LOIs: both unprecedented numbers in our organization’s history.

In the 35+ years since our founding, HCRN has held to a central purpose: to support investigators in managing their multi-center clinical trials. Many of our sponsor-investigators and Clinical Trial Working Group co-chairs are pictured on the cover of this report, and throughout the following pages. We are indebted to them, both for their expertise and for their commitment to building a strong network for collaborative cancer research.

To all our members, supporters, and friends: We hope you enjoy this reflection on our shared accomplishments from the past year. From my perspective, what we have done together, and will yet do, far outshines the challenges that we will meet along the way.



BREAST CANCER

Clinical Trial Working Group

A Message from our Co-Chairs

The HCRN Breast Cancer Working Group strengths include multidisciplinary membership that promotes transdisciplinary concepts. The team has also surveyed membership to determine the areas of interest that are most needed in the field of breast oncology and have tailored our portfolio to those needs. We have also seen increasing participation among members, with new members added frequently to build on the group's collective expertise.

The year 2020 was challenging on many fronts. Despite the many demands among members, the working group remained quite active with consistent participation on our calls, momentum for existing LOIs and protocols, and submission of new proposals. Despite the challenges on each individual, the working group remained cohesive and continues to move forward to develop innovative protocols for our patients with breast cancer.

As our working group is relatively young, we have many concepts approved and in development. The past two years have been focused on building our portfolio, and we see 2021 as a year of implementation. We are hopeful that by the end of the year, many of our approved protocols will be open to accrual and actively recruiting.

To round out our portfolio, we would love to see more momentum in the surgical oncology and translational space. Our portfolio has many innovative concepts across medical and radiation oncology. Engaging our surgical and translational colleagues is a goal for our future.

2020 Publications and Presentations

JAMA Oncology Manuscript:

- Radovich M, Jiang G, Hancock BA, et al. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Pre-planned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. *JAMA Oncol.* 2020;6(9):1410–1415. doi:10.1001/jamaoncol.2020.2295

San Antonio Breast Cancer Symposium:

- *Spotlight Poster Discussion Session:* M Radovich, N Kassem, G Jiang, BA Hancock, BP Schneider. Circulating TP53 mutations in TNBC after neoadjuvant chemotherapy is associated with rapid disease recurrence: Correlative analysis from clinical trial BRE12-158.

Breast Cancer CTWG Co-chairs



Carey
Anders, MD
Duke Cancer
Institute



Erica Stringer-
Reasor, MD
University of
Alabama at
Birmingham



Breast Cancer CTWG at a glance

50+

member investigators

30+

institutions represented

6

active studies & approved
LOI as of 12/31/2020

Learn more:

hoosiercancer.org/breast



GASTROINTESTINAL

Clinical Trial Working Group

A Message from our Co-Chairs

The GI Clinical Trial Working Group is both productive as well as collaborative. We bring a wide berth of expertise in both clinical trial design and translational oncology to our trials that allows for innovative correlative science to be embedded within our trials. Senior and junior faculty work together in such a way that the expertise of the more seasoned trialists is harnessed to train the next generation of GI oncology clinical researchers. We design trials that we know our group can enroll robustly and have a well documented track record of completing and publishing trials.

As the clinical care of our cancer patients underwent huge changes in response to the COVID-19 pandemic, how to continue to provide access to clinical trials for these patients was a top priority for our working group. We discussed challenges that each site was experiencing on our monthly calls and communicated realistic expectations to both the study funders and the sites in terms of enrollment and data collection. Fortunately, despite the need to remain nimble and pivot quickly, we still saw steady clinical trial enrollment on several trials with a published abstract at ASCO GI.

This past year has brought more members from high volume cancer centers to our group, providing a fresh set of ideas for new clinical trial designs. Additionally, we have partnered with both industry and institutional labs to allow for more robust and novel correlative studies to be performed on our study samples, including liquid biopsy ctDNA evaluation, microbiome assays, and immunogenomics.

Proposals targeting metastatic colorectal cancer are always in high demand given the large numbers of patients we see in the clinic with refractory disease. In addition, new targets in biliary cancer will inevitably lead to questions regarding combining targeted therapies with chemotherapy and immunotherapy for these patients. We also have interest in targeting cancers with HRD signatures as well as rationale combinations of immunotherapy agents in gastroesophageal cancer.

2020 Publications and Presentations

Gastrointestinal Cancers Symposium:

- *Trials in Progress Poster: A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination (HR) defective or loss of heterozygosity (LOH) high-metastatic esophageal/GEJ/proximal gastric adenocarcinoma: ESO17-325.*

GI CTWG Co-chairs



Richard Kim, MD
Moffitt Cancer Center



Bassel El-Rayes, MD
Emory University



Autumn J. McRee, MD
University of North Carolina



GI CTWG at a glance

80+
member investigators

40+
institutions represented

11
active studies & approved
LOI as of 12/31/2020

Learn more:
hoosiercancer.org/gi



GENITOURINARY

Clinical Trial Working Group

A Message from our Co-Chairs

The Genitourinary Clinical Trial Working Group is very active with a steady stream of concepts from our engaged investigators. Activated protocols have accrued well overall. Additionally, our studies have largely involved rich correlatives and specimen collection. Like others during the pandemic, we shifted to largely remote meetings and we moved to monthly rather than quarterly meetings. Each protocol within the portfolio was modified to account for COVID-related stipulations such as allowing remote visits and broadening windows for study activities.

A primary goal for the working group in the coming year is to diversify the portfolio. While the bladder portfolio is particularly strong, we hope to further build the RCC and prostate cancer portfolios. We will also consider adaptive trial platforms across tumor types, especially in bladder cancer where we do a lot of neoadjuvant treatment. For each protocol that moves forward through our working group, we plan to embed well-rounded protocol teams that include junior investigators and potentially translational, imaging, and quality of life investigators, as applicable, to allow broader involvement in concept and protocol development. Additionally, we plan to set up regular networking opportunities with investigators and industry collaborators to discuss concepts and potential new protocols.

2020 Publications and Presentations

Journal of Clinical Oncology Manuscript:

- *Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Vs. Placebo After First-Line Chemotherapy in Patients w/ Metastatic Urothelial Cancer.* DOI: 10.1200/JCO.19.03091 *Journal of Clinical Oncology*: GU14-182.

Genitourinary Cancers Symposium:

- *TIP Poster: Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma:* GU17-295.

ASCO Annual Meeting:

- *Oral Abstract: Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients with advanced renal cell carcinoma:* GU16-260.
- *Poster Discussion: Phase II neoadjuvant gemcitabine and pembrolizumab for locally advanced urothelial cancer: Interim results from the cisplatin-ineligible cohort of GU14-188.*
- *Poster: Phase Ib/II neoadjuvant pembrolizumab and chemotherapy for locally advanced urothelial cancer: Final results from cisplatin-eligible cohort of GU14-188.*

ESMO Annual Meeting:

- *Poster: A Phase Ib/2 study of neoadjuvant pembrolizumab and chemotherapy for locally advanced Urothelial Cancer:* GU14-188.
- *Poster: A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE):* GU18-343.

Society of Urologic Oncology Annual Meeting:

- *Poster: Phase 1 trial of durvalumab in combination with BCG or external beam radiation in BCG-unresponsive non-muscle invasive bladder cancer patients:* GU16-243 (ADAPT-BLADDER Trial).

GU CTWG Co-chairs



Matthew Galsky, MD
Icahn School of
Medicine
at Mount Sinai

Noah M. Hahn, MD
Johns Hopkins
University



Guru Sonpavde, MD
Dana-Farber
Cancer Institute

GU CTWG at a glance

75+
member investigators

45+
institutions represented

19
active studies & approved
LOI as of 12/31/2020

Learn more:
hoosiercancer.org/gu



THORACIC

Clinical Trial Working Group

A Message from our Co-Chairs

One of the key strengths of the HCRN Thoracic Clinical Trial Working Group is its breadth and diversity. We have academic centers that have accrued quickly to innovative trials in select patient populations and community sites that give a real-world perspective to our clinical trials portfolio. The nimble nature of the working group allows concepts to move quickly from investigator-initiated LOI submission to fully funded protocols and clinical trials open for enrollment.

We have always communicated remotely, as our member investigators represent institutions nationwide. With the challenges of the past year we have been able to incorporate better remote conferencing tools to make our meetings more engaging and productive.

The working group has a broad portfolio, but we see opportunities in a few key areas. Particularly, we can develop impactful studies in the head and neck space, and we can increase our multimodality studies and answer questions relating to supportive care with our patient populations.

2020 Publications and Presentations

Cancer Manuscript:

- Durm, GA, Jabbour, SK, Althouse, SK, Liu, Z, Sadiq, AA, Zon, RT, Jalal, SI, Kloecker, GH, Williamson, MJ, Reckamp, KL, Langdon, RM, Kio, EA, Gentzler, RD, Adesunloye, BA, Harb, WA, Walling, RV, Titzer, ML, Hanna, NH. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN14-179. *Cancer*. 2020; 126: 4353–4361. <https://doi.org/10.1002/cncr.33083>.

Clinical Lung Cancer Manuscript:

- B Anouti, S Althouse, G Durm, N Hanna. Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179. *Clinical Lung Cancer*, Volume 21, Issue 3, 2020, Pages 288-293, ISSN 1525-7304, <https://doi.org/10.1016/j.clc.2019.06.009>.

ASCO Annual Meeting:

- Poster Session: N Shukla, SK Althouse, AA Sadiq, SI Jalal, SK Jabbour, R Zon, GH Kloecker, WB Fisher, KL Reckamp, EA Kio, RM Langdon, B Adesunloye, RD Gentzler, NH Hanna, GA Durm. The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC: an analysis from HCRN LUN14-179.

Thoracic CTWG

Co-chairs



Greg Durm, MD
Indiana University
School of
Medicine



Mary Jo Fidler, MD
Rush Medical
College



Ryan Gentzler, MD
University of
Virginia School
of Medicine

Thoracic CTWG

at a glance

60+

member investigators

40+

institutions represented

9

active studies & approved
LOI as of 12/31/2020

Learn more:

hoosiercancer.org/thoracic



Clinical Trial Working Groups

Melanoma CTWG

Co-chairs



Ragini R. Kudchadkar, MD
Emory University

Timothy Kuzel, MD
Rush University



April Salama, MD
Duke University

Melanoma CTWG

at a glance

35+

member investigators

25+

institutions represented

4

*active studies & approved
LOI as of 12/31/2020*

Learn more:

hoosercancer.org/melanoma




Correlative Sciences CTWG

Co-chairs



Thomas G. Sors, PhD
Purdue University

David J. McConkey, PhD
Johns Hopkins University



Correlative Sciences CTWG

at a glance

35+

member investigators

20+

institutions represented

Learn more:

hoosercancer.org/correlative

A Message From our Correlative Sciences Co-Chairs

The HCRN Correlative Sciences working group includes a wide diversity of oncologists and basic science investigators who provide expertise on the best correlative questions to ask and the most appropriate samples to be collected for the studies we review. This diverse, nationwide community allows us to be versatile in the support we provide for oncology trials.

Over the past year, our team continued our recurrent virtual calls and worked closely with investigators as they planned their studies. We introduced speakers who highlighted technologies relevant to correlative sciences. In the coming year, we will explore opportunities to leverage existing collaborations between institutions and health networks to strengthen the statistical robustness of our studies. We also plan to increase our collaboration with data scientists throughout the HCRN network.

Myeloid CTWG

Co-chairs



Matthew Foster, MD
University of North Carolina

Joshua Zeidner, MD
University of North Carolina



Myeloid CTWG

at a glance

10+

member investigators

8

institutions represented

Learn more:

hoosercancer.org/myeloid

Research Collaborations

Big Ten Cancer Research Consortium (Big Ten CRC)



The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities. The goal of the Big Ten CRC is to create a unique team-research culture to

drive science rapidly from ideas to new approaches to cancer treatment. Within this innovative environment, today's research leaders collaborate with and mentor the research leaders of tomorrow with the unified goal of improving the lives of all patients with cancer. Learn more: bigtencrc.org.

HCRN serves as administrative headquarters for the Big Ten CRC.

Translational Breast Cancer Research Consortium (TBCRC)



The Translational Breast Cancer Research Consortium is a collaborative group founded in 2005 to conduct innovative and high-impact clinical trials for breast cancer. The TBCRC is composed of 19 clinical sites; five core working groups focusing on correlative science and breast cancer phenotypes; two interest groups focusing on patient-reported outcomes and immuno-oncology; working groups for patient advocates, study coordinators, and contracts/administrators; and a central office. Collectively, these groups work to

foster trial development in a collegial environment that enhances cross-institutional collaboration.

Learn more: pub.emmes.com/study/bcrc/.

HCRN provides trial management and support to the TBCRC.

Bladder Cancer Genomics Consortium (BCGC)



The Bladder Cancer Advocacy Network launched the Bladder Cancer Genomics Consortium in 2017. The BCGC's ultimate goal is to provide the opportunity for every patient to be an exceptional responder to personalized therapy while advancing collaborative research to support the development of life-saving treatments for bladder cancer. Learn more: bcan.org/bladder-cancer-genomics-consortium/.

HCRN developed and manages a genomically driven sample collection study for the BCGC.

Midwest Melanoma Partnership (MMP)



The Midwest Melanoma Partnership (MMP) is a multi-institutional collaboration of physicians, scientists, and patient advocates dedicated to the development of improved therapies for patients with malignant melanoma. Learn more: midwestmelanoma.org.

HCRN provides trial management and support to the MMP.

Big Ten Cancer Research Consortium



The Big Ten cancer centers have united . . .

to transform the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities. The goal of the Big Ten Cancer Research Consortium is to create a unique team-research culture to drive science rapidly from ideas to new approaches to cancer treatment. Within this innovative environment, today's research leaders collaborate with and mentor the research leaders of tomorrow with the unified goal of improving the lives of all patients with cancer.

2020 Publications and Presentations

Manuscripts:

- *Journal of Clinical Oncology* (BTCRC-GU14-003)

Gastrointestinal Cancers Symposium:

- 2 posters (BTCRC-ESO14-012, BTCRC-GI18-149)

Genitourinary Cancers Symposium:

- 1 poster (BTCRC-GU15-023)

ASCO Annual Meeting:

- 2 poster discussions (BTCRC-LUN16-081, BTCRC-GYN15-013)
- 2 posters (BTCRC-ESO14-012, BTCRC-AML17-113)

ESMO:

- 1 poster (BTCRC-GU16-043)

Big Ten CRC at a glance

300+

*investigators in Clinical
Trial Working Groups*

500+

*patients enrolled to date
on Big Ten CRC studies*

30+

*Big Ten CRC studies
opened to date*

Learn more:

www.bigtenrc.org

facebook.com/bigtenrc

twitter.com/bigtenrc

Studies Opened to Accrual in 2020


GI18-333



Title: Phase 2 study of novel SE-QUEnced immunotherapy (pembrolizumab) with anti-angiogenesis and chemotherapy in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma (SEQUEL).

Sponsor-Investigator: Harry Yoon, MD
Lead Institution: Mayo Clinic

BTCRC-GI15-067



Title: A phase II study to evaluate the efficacy of liposomal irinotecan in combination with oxaliplatin, leucovorin, and 5-fluorouracil for patients with locally advanced pancreatic carcinoma.

Sponsor-Investigator: Nelson S. Yee, MD, PhD, RPh
Lead Institution: Penn State Cancer Institute

GI19-405



Title: A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC).

Sponsor-Investigator: Aiwu Ruth He, MD
Lead Institution: Georgetown University

BTCRC-LUN18-153



Title: A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm.

Sponsor-Investigator: Greg Durm, MD
Lead Institution: Indiana University

GU18-343



Title: A Phase 2 Study of Cabozantinib in Combination With Atezolizumab as Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer (ABATE).

Sponsor-Investigator: Deepak Kilari, MD
Lead Institution: Froedtert & Med. College of Wisconsin

BTCRC-LUN19-396



Title: Phase II Study of Adjuvant Treatment w/ Cisplatin-based Chemotherapy + Concomitant Atezolizumab in pts w/ Stage I (Tumors \geq 4cm), IIA, IIB, Select IIIA [T3N1, T4N0-1] Resected NSCLC and Clearance of ctDNA.

Sponsor-Investigator: Nasser Hanna, MD
Lead Institution: Indiana University

LUN18-357



Title: Induction durvalumab followed by chemoradiation and consolidation durvalumab (MEDI4736) for stage III non-small cell lung cancer.

Sponsor-Investigator: Rachel E. Sanborn, MD
Lead Institution: Providence Cancer Institute

BTCRC-LYM17-145



Title: Phase Ib dose de-escalation study of PI3K alpha/delta inhibitor Copanlisib given in combination with immunotherapeutic agents Nivolumab and Rituximab in patients w/ relapsed/refractory indolent lymphoma.

Sponsor-Investigator: Tycel Phillips, MD
Lead Institution: University of Michigan

Our Contributors

Thank you to all who have contributed to Hoosier Cancer Research Network. We are grateful for your commitment of time and resources to help us fulfill our mission. Your generous support strengthens our ability to fund investigator-initiated research. Learn how you can contribute at www.hoosercancer.org/make-a-difference/.

Contributions Received in 2020

Amazon Smile
Evangeline Antonopoulos
JoLynn Bahr
The Benevity Community Impact Fund (Microsoft)
The Blackbaud Giving Fund
Brent Barta (West 10th Dental Group)
Maura Buckley — *In memory of George F. Buckley*
Cynthia Burkhardt — *In memory of Mr. John H. Waffle*
Noreen Cahalane (Merz Branding)
Anita Camic
Ali Coffey — *In memory of Martha Blank*
Kenneth Cornetta
Randal Dillinger — *In memory of Bryn Marlow*
Karen Dutcher
Christopher A. Fausel — *In memory of Mr. Gerald W. Fausel*
Fidelity Charitable — *In honor of Dr. John Eliades*
Bill, Bob, John and Janet Fisher — *In memory of Mrs. Fannie Beall*
Charles Fletcher Fox
Tom Goins — *In honor of Dr. Jeanne M. Schilder*
Sara Jo Grethlein
Pamela Griffin — *In memory of Edward J. Griffin*
Patricia Kneebone
Chris LeMasters
Ashley Lucas — *In honor of Mr. Mark Breedlove*
Cara A. Martin — *In memory of Skip Herring*

Julie Martin — *In honor of Dr. Jeanne M. Schilder*
Mary A. Maxwell — *In honor of Dr. Jeanne M. Schilder*
Sarah Maxwell
Rakesh Mehta
Daniel Jerome Monnin — *In memory of Carl Joseph Monnin; In honor of Dr. Jeanne M. Schilder*
My Tribute Gift
Network for Good
Bert O'Neil
Megan Reimann
Jessica Roy
Anita Rush-Taylor
Daniel Rushing
David Sams
Jennifer Sams
Jeanne Schilder — *In memory of Kelly McCombs Motz*
Bradley R. Schutz
Theodore and Barbara Stansbury
Donald Vanderkolk — *In memory of Sheryl Dillinger*
Heather Warhurst
Christopher Wayne
Lisa Leanne Wood — *In memory of Mrs. Alice Hoffman*
Your Cause LLC (Trustee for Wells Fargo Community Support Campaign)



Make a lasting difference with a planned gift

Please consider making a gift from your estate to Hoosier Cancer Research Network. Your generosity will help ensure researchers have the support they need to explore critical questions in cancer research. Learn more: hoosercancer.org/mylegacy

Our Member Network

Alabama

- UAB Comprehensive Cancer Center, Birmingham

Arizona

- BCG Oncology, P.C., Phoenix
- Ironwood Cancer & Research Centers, Phoenix
- University of Arizona Cancer Center
- Yuma Regional Cancer Center, LLC, Yuma

Arkansas

- Genesis Cancer Center, Hot Springs

California

- Cedars-Sinai Medical Center, Los Angeles
- City of Hope, Duarte
- Marin Cancer Care, Greenbrae
- Moore's Cancer Center at UC San Diego Health
- Prostate Oncology Specialists, Inc., Marina Del Rey
- Salinas Valley Memorial Healthcare System, Salinas
- Stanford University, Stanford
- USC Norris Comprehensive Cancer Center, Los Angeles

Colorado

- University of Colorado Cancer Center, Aurora

Connecticut

- Yale Cancer Center, New Haven

Florida

- Memorial Breast Cancer Center at Memorial Regional Hospital, Hollywood
- Moffitt Cancer Center, Tampa
- Sylvester Comprehensive Cancer Center at the University of Miami
- UF Health Cancer Center, Orlando
- University of Florida Health Cancer Center, Gainesville

Illinois

- Illinois CancerCare, PC, Galesburg
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- Rush University Medical Center, Chicago
- The University of Chicago Medical Center
- University of Illinois Cancer Center, Chicago

Indiana

- American Health Network, Indianapolis
- Baptist Health Floyd Cancer Care Center, New Albany
- Community Health Network, Inc. Cancer Centers, Indianapolis
- Community Healthcare System, Munster
- Fort Wayne Medical Oncology & Hematology
- Good Samaritan, Vincennes
- Goshen Center for Cancer Care
- Horizon Oncology Research LLC, Lafayette
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- IU Health Arnett Cancer Centers, Lafayette
- IU Health Ball Memorial Cancer Center, Muncie
- IU Health Cancer Centers Bloomington
- IU Health Central Indiana Cancer Centers, Indianapolis
- Memorial Hospital of South Bend and Elkhart General Hospital
- Oncology Hematology Associates of Southwest Indiana, Newburgh
- Parkview Research Center, Fort Wayne
- St. Vincent, Indianapolis
- St. Vincent Anderson Regional Hospital, Anderson

Iowa

- University of Iowa Holden Comprehensive Cancer Center, Iowa City

Kansas

- Cancer Center of Kansas, Wichita
- University of Kansas Medical Center, Kansas City

Kentucky

- Univ. of Louisville/James Brown Cancer Center, Louisville

Louisiana

- Ochsner, New Orleans

Maryland

- Meritus Center for Clinical Research / John R. Marsh Cancer Center, Hagerstown
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore

Massachusetts

- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Tufts Medical Center, Boston

Michigan

- Barbara Ann Karmanos Cancer Center, Detroit
- Henry Ford Health System, Detroit
- Michigan Center of Medical Research, Farmington Hills
- The Cancer Center at Metro Health Village, Wyoming
- University of Michigan Rogel Cancer Center, Ann Arbor

Minnesota

- HealthPartners Institute, Minneapolis
- Masonic Cancer Center, Univ. of Minnesota, Minneapolis

Missouri

- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis

Nebraska

- Fred & Pamela Buffett Cancer Center (University of Nebraska), Omaha
- Methodist Hospital, Omaha
- Nebraska Cancer Specialists, Omaha
- Urology Cancer Center and GU Research Network, Omaha

New Hampshire

- Dartmouth-Hitchcock Norris Cotton Cancer Center, Lebanon

New Jersey

- Atlantic Health System, Morristown
- John Theurer Cancer Center at Hackensack Meridian Health, Hackensack
- Penn Medicine | Virtua Cancer Program
- Regional Cancer Care Associates, LLC, Cherry Hill
- Rutgers Cancer Institute of New Jersey, New Brunswick
- Summit Medical Group Cancer Center, Florham Park


New Mexico

- University of New Mexico Comprehensive Cancer Center, Albuquerque

New York

- Columbia University Irving Medical Center, New York
- Icahn School of Medicine at Mount Sinai, New York
- Integrated Medical Professionals, PLLC, Melville

Our Member Network



Learn more at:
hoosiercancer.org/members

- ▀ Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
- ▀ Memorial Sloan Kettering Cancer Center, New York
- ▀ Montefiore Medical Center
- ▀ New York University Cancer Institute, New York
- ▀ Roswell Park Cancer Institute, Buffalo
- ▀ University of Rochester - Wilmot Cancer Institute

North Carolina

- ▀ Duke Cancer Institute
- ▀ Novant Health Oncology Specialists, Winston-Salem
- ▀ University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
- ▀ Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston-Salem

Ohio

- ▀ Cleveland Clinic Cancer Center
- ▀ The Ohio State University, Columbus
- ▀ University Hospitals Seidman Cancer Center, Cleveland
- ▀ University of Cincinnati Cancer Center

Oklahoma

- ▀ Stephenson Cancer Center at the Univ. of Oklahoma, Oklahoma City

Oregon

- ▀ Knight Cancer Institute at Oregon Health & Science University, Portland
- ▀ Providence Cancer Institute, Portland

Pennsylvania

- ▀ Allegheny Health Network, Pittsburgh
- ▀ Fox Chase Cancer Center, Philadelphia
- ▀ Gettysburg Cancer Center, Gettysburg
- ▀ Penn Medicine Abramson Cancer Center, Philadelphia
- ▀ Penn State Cancer Institute, Hershey
- ▀ Thomas Jefferson University / Sidney Kimmel Cancer Center, Philadelphia
- ▀ UPMC Hillman Cancer Center, Pittsburgh

South Carolina

- ▀ Medical University of South Carolina / Hollings Cancer Center, Charleston

Tennessee

- ▀ Erlanger Health System, Chattanooga
- ▀ Vanderbilt-Ingram Cancer Center, Nashville
- ▀ West Cancer Center, Memphis

Texas

- ▀ Baylor College of Medicine, Houston
- ▀ Joe Arrington Cancer Research and Treatment Center, Lubbock
- ▀ MD Anderson Cancer Center, Houston
- ▀ Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
- ▀ UT Health San Antonio MD Anderson Cancer Center
- ▀ UT Medical Branch at Galveston
- ▀ UT Southwestern Harold C. Simmons Comp. Cancer Center, Dallas

Utah

- ▀ Huntsman Cancer Institute at University of Utah, Salt Lake City

Virginia

- ▀ University of Virginia Cancer Center, Charlottesville
- ▀ Virginia Commonwealth University, Richmond
- ▀ Virginia Oncology Associates, Norfolk

Washington

- ▀ Fred Hutchinson Cancer Research Center, Seattle

Washington, D.C.

- ▀ George Washington University Cancer Center
- ▀ Georgetown University Lombardi Comprehensive Cancer Center

Wisconsin

- ▀ Aurora Research Institute, LLC, Milwaukee
- ▀ Clement J. Zablocki VA Medical Center, Milwaukee
- ▀ Froedtert & the Medical College of Wisconsin, Milwaukee
- ▀ University of Wisconsin Carbone Cancer Center, Madison

hoosierSM
CANCER RESEARCH NETWORK

500 N. Meridian Street, Suite 100, Indianapolis, IN 46204

P: (317) 921-2050 **F:** (317) 921-2053 **E:** contact@hoosiercancer.org

www.hoosiercancer.org